Bli medlem
Bli medlem

Du är här


AroCell nomination committee for the AGM 2022

AroCell AB (publ.) publishes the nomination committee’s composition for the AGM in 2022.

The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on June 3, 2021, consists of:
• Clas Runnberg, represents his own shares
• Jon Eiken, represents his own shares
• Michael Lönn, represents his own shares
The nomination committee shall, before the annual general meeting 2022, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, the election of auditors, the determination of fees, and matters pertaining thereto.
For more information, please visit:
Nomination committee - AroCell TK 210 ELISA
Shareholders who wish to submit proposals to the nomination committee for the annual general meeting 2022 can do so by e-mail to (header ”AroCell´s nomination committee”). Proposals should be submitted to the nomination committee before January 31st, 2022.
For further information, please contact:
Anders Hultman, CEO at AroCell
The information was submitted for publication, through the agency of the contact person set out above, at 15:00 on December 03, 2021.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser:, +46 (0)8 121 576 90. For more information;


AroCell nomination committee for the AGM 2022

Författare MFN